Abattis Bioceuticals Corp. announced that the research being done in conjunction with the University of British Columbia and Mitacs is close to completing their phase of testing. In First Quarter 2018, Abattis announced a research study in partnership with Mitacs to explore the development of nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil. The research and development work has been led by scientists from Abattis and the Faculty of Land and Food Systems at the University of British Columbia ("UBC"). Phase 1 of the study was a comparison of studies of transmucosal (stomach lining) vs sublingual (under the tongue) absorption of cannabinoids. The focus of this study is to confirm that sublingual absorption is indeed superior in terms of providing a higher percentage of successful cannabinoid reception into the bloodstream, providing much faster medical benefits through increasingly efficient absorption. Abattis is currently in the running to be one of the first bioceuticals companies to publish public research on sublingual and transmucosal absorption of cannabinoids. Additional testing has also been done in regard to the measurement of the absorption of cannabinoids and omega3 and omega6 into the bloodstream. Current research has demonstrated that cold pressed hemp oil and added antioxidants (omega3 and omega6) have proved to be effectively paired, adding substantial stability to the cannabinoids. Samples were also subject to extensive heat testing to speed up degradation, concluding that stabilized cannabis oil with omega3 and omega6 additives lasted longer over time and provided increased potency.